Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

No Impact of Pre-Existing Cardiovascular Disease on Prescribing Patterns of Sulphonylureas in Denmark - A Registry-based Nationwide Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Drug-related challenges following primary total hip and knee arthroplasty

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

    Research output: Contribution to journalReviewResearchpeer-review

  4. Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hemoglobin A1c-levels and subsequent risk of depression in individuals with and without diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiovascular risk management: A nationwide register-based study of patterns and secular changes of discontinuation prior to death

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  4. DISCONTINUATION OF CARDIOPROTECTIVE MEDICATION PRIOR TO DEATH, IN THE VERY ELDERLY: A NATIONWIDE REGISTER-BASED STUDY

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  5. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Uncertainty exists regarding cardiovascular (CV) safety of sulphonylureas (SUs) as reflected in package labels and treatment guidelines. This study evaluated clinical treatment practice for SUs by analysing prescription patterns for SUs relative to patient history of CV disease (CVD). Patients in Denmark initiating treatment with SU or other anti-hyperglycaemic drugs during 2006-2012 were retrospectively identified using national health registries. Pre-existing (previous 12 years) overall CVD, coronary heart disease (CHD) and myocardial infarction (MI) were subsequently identified. Proportion of patients with pre-existing CVD was compared between new users of SU and new users of other anti-hyperglycaemic drugs. In total, 50,425 (42.2% females, mean±SD age 63.3±13.5 years) and 190,438 (46.5% females, age 60.3±15.0 years) patients initiated treatment with SU or other anti-hyperglycaemic drugs, respectively, during 2006-2012. The number of patients initiating SU treatment decreased by 63% during 2006-2012. The proportion of patients with pre-existing CVD varied between 46.9 and 49.8% among new SU users versus 39.9 and 44.8% among new users of other anti-hyperglycaemic drugs. Corresponding proportions for CHD (17.9-19.9% versus 15.4-16.9%) and MI (6.3-7.5% versus 5.8-6.2%) showed the same pattern. Excluding new gliclazide users (9.6% of all new SU users) from the SU definition did not alter the results. Despite a potentially increased CV risk associated with use of SUs, pre-existing CVD did not decrease clinicians' relative prescriptions of SUs. This article is protected by copyright. All rights reserved.
Original languageEnglish
JournalBasic & Clinical Pharmacology & Toxicology Online
Volume122
Issue number6
Pages (from-to)606-611
Number of pages6
ISSN1742-7843
DOIs
Publication statusPublished - 12 Jan 2018

Bibliographical note

This article is protected by copyright. All rights reserved.

    Research areas

  • Journal Article

ID: 56691203